查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲伴同性诊断市场：按应用、按最终用户、按技术、按国家 - 分析和预测（2023-2033）
市场调查报告书
商品编码
1578771

欧洲伴同性诊断市场：按应用、按最终用户、按技术、按国家 - 分析和预测（2023-2033）

Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 73 Pages | 商品交期: 1-5个工作天内

价格

2023 年欧洲伴同性诊断市场规模为 11.165 亿美元。

预计2023年至2033年该市场将以12.30%的复合年增长率成长，2033年达到35.621亿美元。生物医学影像的进步、伴同性诊断产品认证数量的增加以及癌症发病率的上升正在推动欧洲伴同性诊断市场的扩张。这些因素是支持伴同性诊断和精准医疗在个人化癌症治疗中广泛使用的主要力量。

主要市场统计数据
预测期 2023-2033
2023年评估 11.165 亿美元
2033 年预测 35.621 亿美元
复合年增长率 12.3%

对精准医疗的需求不断增长和癌症发病率上升正在推动欧洲伴同性诊断行业的发展。特别是在肿瘤学领域，伴同性诊断对于透过识别最有可能从特定药物中受益的患者来客製化治疗方法至关重要。伴同性诊断是改善治疗结果的关键工具。因为整个欧洲癌症发生率的上升增加了对此类针对性药物的需求。

新的伴同性诊断正在得到欧洲监管机构的积极核准，这正在推动市场成长。由于增强型生物医学影像方法和分子诊断（包括次世代定序（NGS））的开拓，该市场正在扩大。这些进展将使生物标誌物的识别更加精确，从而实现更精确和客製化的治疗。

伴同性诊断不仅在癌症领域变得流行，而且在感染疾病和循环系统疾病等其他治疗领域也越来越流行。由于研发支出的增加和有利的法律规范，欧洲的伴同性诊断市场预计将逐步扩大，扩大个体化医疗在整个欧洲大陆的使用并提高患者的治疗效果。

该报告研究了欧洲伴同性诊断市场，并提供了市场概述，包括按应用、最终用户、技术、国家和参与市场的公司概况分類的趋势。

目录

执行摘要

第一章 市场

  • 趋势：当前和未来的影响评估
  • 供应链概览
  • 研究发展回顾
  • 监管状况
  • 从历史角度进行伴同性诊断
  • 伴同性诊断 (CDx) 开发的组成部分
  • 伴同性诊断 (CDx)：未来的可能性
  • 市场动态概览

第二章 区域

  • 区域概况
  • 促进因素和抑制因素
  • 欧洲

第三章市场－竞争基准化分析与公司概况

  • 未来展望
  • 地理评估
    • bioMerieux
    • F. Hoffmann-La Roche Ltd
    • ICON plc
    • QIAGEN NV

第四章调查方法

Product Code: BHP2367SS

Introduction to Europe Companion Diagnostics Market

The Europe companion diagnostics market was valued at $1,116.5 million in 2023 and is expected to reach $3,562.1 million by 2033, growing at a CAGR of 12.30% between 2023 and 2033. Advances in biomedical imaging, a rise in companion diagnostics product approvals, and the rising prevalence of cancer are driving the companion diagnostics market's expansion in Europe. These elements are major forces behind the region's growing use of companion diagnostics and precision medicine in individualized cancer care.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$1,116.5 Million
2033 Forecast$3,562.1 Million
CAGR12.3%

The growing desire for precision medicine and the rising incidence of cancer are driving the companion diagnostics industry in Europe. Particularly in oncology, companion diagnostics are essential for tailoring treatment regimens by identifying patients who are most likely to benefit from particular medicines. Companion diagnostics is a crucial tool for improving treatment outcomes because the increase in cancer incidence throughout Europe has increased the need for such focused medicines.

New companion diagnostics devices are being actively approved by European regulatory bodies, which is driving the market's growth. The market is expanding due to technological developments in molecular diagnostics, including enhanced biomedical imaging methods and next-generation sequencing (NGS). These developments make it possible to identify biomarkers more precisely, which enables more precisely tailored treatments.

Companion diagnostics are becoming popular not only in oncology but also in other treatment domains as infectious and cardiovascular illnesses. The companion diagnostics market in Europe is anticipated to expand gradually due to rising R&D expenditures and a favorable regulatory framework, expanding the use of customized medicine and boosting patient outcomes throughout the continent.

Market Segmentation

Segmentation 1: by Technology

  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In-Situ Hybridization (ISH)
  • Next-Generation Sequencing (NGS)
  • Others

Segmentation 2: by Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Stomach Cancer
  • Melanoma
  • Others

Segmentation 3: by End User

  • Pharmaceutical and Biotechnology Companies
  • Reference Laboratories and Hospitals
  • Others

Segmentation 4: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe companion diagnostics market has been segmented based on various categories, such as technology, application, end user, and country.

Competitive Strategy: The Europe companion diagnostics market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Europe companion diagnostics market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • bioMerieux
  • F. Hoffmann-La Roche Ltd
  • ICON Plc
  • QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Companion Diagnostics Market Trend Analysis
    • 1.1.2 Implementation of Liquid Biopsy-Based Companion Diagnostics
    • 1.1.3 Combining Artificial Intelligence and Companion Diagnostics
  • 1.2 Supply Chain Overview
    • 1.2.1 Value Chain Analysis
  • 1.3 Research and Development Review
    • 1.3.1 Patent Filing Trend (by Country, Year)
  • 1.4 Regulatory Landscape
    • 1.4.1 Legal Requirements and Framework by the FDA
    • 1.4.2 Legal Requirements and Framework by the EMA
  • 1.5 CDx from a Historical Perspective
  • 1.6 Constituents for Companion Diagnostics (CDx) Development
  • 1.7 Companion Diagnostics (CDx): Future Potential
  • 1.8 Market Dynamics Overview
    • 1.8.1 Market Drivers
      • 1.8.1.1 Rising Prevalence of Cancer Cases
      • 1.8.1.2 Increasing Product Approvals in the Field of Companion Diagnostics
      • 1.8.1.3 Advancing Biomedical Imaging as the Driving Force for Precision Medicine's Companion Diagnostics
    • 1.8.2 Market Restraints
      • 1.8.2.1 Uncertain Reimbursement Scenario
      • 1.8.2.2 Stringent Regulatory Approval Processes
    • 1.8.3 Market Opportunities
      • 1.8.3.1 Progress in Companion Diagnostics Driven by Continuous Development and Technological Advancements
      • 1.8.3.2 Introduction of Epigenomics-Based Companion Diagnostics

2 Regions

  • 2.1 Regional Summary
  • 2.2 Drivers and Restraints
  • 2.3 Europe
    • 2.3.1 Regional Overview
    • 2.3.2 Driving Factors for Market Growth
    • 2.3.3 Factors Challenging the Market
    • 2.3.4 Application
    • 2.3.5 Product
    • 2.3.6 France
    • 2.3.7 Application
    • 2.3.8 Product
    • 2.3.9 Germany
    • 2.3.10 Application
    • 2.3.11 Product
    • 2.3.12 U.K.
    • 2.3.13 Application
    • 2.3.14 Product
    • 2.3.15 Spain
    • 2.3.16 Application
    • 2.3.17 Product
    • 2.3.18 Italy
    • 2.3.19 Application
    • 2.3.20 Product
    • 2.3.21 Rest-of-Europe
    • 2.3.22 Application
    • 2.3.23 Product

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Next Frontiers.....
  • 3.2 Geographic Assessment
    • 3.2.1 bioMerieux
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 F. Hoffmann-La Roche Ltd
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products/Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 ICON plc
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products/Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 QIAGEN N.V.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products/Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.1 Target Customers
      • 3.2.4.2 Key Personnel
      • 3.2.4.3 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecasta

List of Figures

  • Figure 1: Europe Companion Diagnostics Market, $Million, 2023, 2026, and 2033
  • Figure 2: Europe Companion Diagnostics Market (by Application), $Million, 2022, 2026, and 2033
  • Figure 3: Europe Companion Diagnostics Market (by Technology), $Million, 2022, 2026, and 2033
  • Figure 4: Europe Companion Diagnostics Market (by End User), $Million, 2022, 2026, and 2033
  • Figure 5: Key Industrial Developments in Companion Diagnostics Market, 2023
  • Figure 6: Key Aspects Related to Liquid Biopsy-Based Companion Diagnostics
  • Figure 7: Applications of Digital Diagnostics
  • Figure 8: Supply Chain and Risks within the Supply Chain
  • Figure 9: Europe Companion Diagnostics Market (by Country), January 2021-December 2023
  • Figure 10: Europe Companion Diagnostics (by Year), January 2021-December 2023
  • Figure 11: Evolution of Companion Diagnostics
  • Figure 12: Components Required to Develop Companion Diagnostics
  • Figure 13: Future Prospects of CDx
  • Figure 14: Impact Analysis of Market Navigating Factors, 2023-2033
  • Figure 15: Factors Impacting Reimbursement Scenario
  • Figure 16: Advancements in Companion Diagnostics
  • Figure 17: Future Outlook of Epigenomics
  • Figure 18: Europe Companion Diagnostics Market, $Million, 2022-2033
  • Figure 19: France Companion Diagnostics Market, $Million, 2022-2033
  • Figure 20: Germany Companion Diagnostics Market, $Million, 2022-2033
  • Figure 21: U.K. Companion Diagnostics Market, $Million, 2022-2033
  • Figure 22: Spain Companion Diagnostics Market, $Million, 2022-2033
  • Figure 23: Italy Companion Diagnostics Market, $Million, 2022-2033
  • Figure 24: Rest-of-Europe Companion Diagnostics Market, $Million, 2022-2033
  • Figure 25: Strategic Initiatives, 2021-2023
  • Figure 26: Share of Strategic Initiatives, 2021-2023
  • Figure 27: Data Triangulation
  • Figure 28: Top-Down and Bottom-Up Approach
  • Figure 29: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Companion Diagnostics Market, Opportunities
  • Table 3: Some of FDA Approved Liquid Biopsy CDx Tests
  • Table 4: Cancer Cases Expected between 2020 and 2040
  • Table 5: Product Approvals in the Field of Companion Diagnostics
  • Table 6: Companion Diagnostics Preparation (by Region), $Million, 2022-2033
  • Table 7: Europe Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 8: Europe Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 9: Europe Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 10: France Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 11: France Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 12: France Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 13: Germany Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 14: Germany Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 15: Germany Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 16: U.K. Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 17: U.K. Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 18: U.K. Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 19: Spain Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 20: Spain Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 21: Spain Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 22: Italy Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 23: Italy Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 24: Italy Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 25: Rest-of-Europe Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 26: Rest-of-Europe Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 27: Rest-of-Europe Companion Diagnostics Market (by Technology), $Million, 2022-2033